Carta Healthcare Closes $18.25M for Data Abstraction AI

Manual clinical data abstraction is a prime target for AI automation, and Carta Healthcare is looking to hit the center of the bullseye after raising $18.25M of Series B1 funding.

Carta’s data abstraction platform leverages AI and a team of expert abstractors to automate the collection of clinical data and surface actionable insights.

  • The platform converts both structured and unstructured data into standardized datasets, giving healthcare orgs a foundation of high-quality data to build on. 

Although AI’s potential in the data abstraction arena has attracted an army of new competitors, Carta’s been duking it out against manual workflows since 2017.

  • That gave it a big head start to refine its tech and build trust with partners, many of which participated in the round, including MemorialCare, Memorial Hermann, and MGB.
  • Carta plans to put the new capital toward expanding its customer footprint, particularly in the life sciences market where it can help match patients to clinical trials using AI it acquired from Realyze.

The Takeaway

Traditional methods of data abstraction are about as labor-intensive and time-consuming as you can imagine, which makes them ideal targets for AI solutions and startups like Carta that are bringing them to market.

We’re testing a new format today – let us know if you prefer two shorter Top Stories or one longer Top Story with this quick survey!

More Reasoning, More Hallucinations for LLMs

Better reasoning apparently doesn’t prevent LLMs from spewing out false facts.  

Independent testing from AI firm Vectara showed that the latest advanced reasoning models from OpenAI and DeepSeek hallucinate even more than previous models.

  • OpenAI’s o3 reasoning model scored a 6.8% hallucination rate on Vectara’s test, which asks the AI to summarize various news articles.
  • DeepSeek’s R1 fared even worse with a 14.3% hallucination rate, an especially poor performance considering that its older non-reasoning DeepSeek-V2.5 model clocked in at 2.4%.
  • On OpenAI’s more difficult SimpleQA tests, o3 and o4-mini hallucinated between 51-79% of the time, versus just 37% for its GPT-4.5 non-reasoning model.

OpenAI positions o3 as its most powerful model because it’s a “reasoning” model that takes more time to “think” and work out its answers step-by-step.

  • This process produces better answers for many use cases, but these reasoning models can also hallucinate at each step of their “thinking,” giving them even more chances for incorrect responses.

The Takeaway

Even though the general purpose models studied weren’t fine-tuned for healthcare, the results raise concerns about their safety in clinical settings – especially given how many physicians report using them in day-to-day practice.

We’re testing a new format today – let us know if you prefer two shorter Top Stories or one longer Top Story with this quick survey!

Teladoc Adds In-Network Therapy With Uplift Acquisition

Teladoc wrapped up a bumpy Q1 with the acquisition of virtual therapy provider Uplift, a move that it hopes will help turnaround its persistently problematic BetterHelp segment.

UpLift provides virtual therapy, psychiatry, and medication management services – all crucially covered by most major commercial payors, as well as Medicare and Medicaid.

  • The deal adds over 100M covered lives and a network of 1,500 mental health clinicians, which Teladoc plans to integrate with BetterHelp to give its customers access to in-network treatment options.

The $30M acquisition shores up one of the most glaring weaknesses of BetterHelp’s cash-pay-only DTC mental health offerings, with Teladoc citing out-of-pocket costs as one of the primary barriers preventing potential customers from signing up.

  • UpLift generated $15M of revenue last year – a drop in the bucket compared to the $1B that BetterHelp brought in – but it’s anyone’s guess as to how much of a lift Teladoc will see from the “significantly higher conversion rates” it expects for new members.

In the wake of the pandemic, BetterHelp has eroded from one of Teladoc’s most promising assets to a constant pain point on investor calls, including a $790M impairment in Q2 2024.

  • Setting aside the scathing short report that accused BetterHelp therapists of using ChatGPT to respond to patients during sessions, the segment’s also been facing pressure from rising ad costs that have made it difficult to keep user growth steady.
  • Teladoc now expects BetterHelp revenue to fall between 7.5% to 11.25% next quarter, before returning to form later in the year thanks to stickier relationships courtesy of Uplift.

It’s also interesting to see Teladoc pick up another company at a 2X revenue multiple after paying the same rate for Catapult Health back in February.

  • Not exactly a lofty valuation for an established company with real revenue, especially considering the fairytale multiples we’re seeing startups command in AI Land.

The Takeaway

Acquiring Uplift’s existing payor partnerships should definitely accelerate BetterHelp’s ability to start accepting insurance, a much needed move given its recent difficulty wrangling new customers. Although an immaculate M&A track record isn’t something that Teladoc has going for it, this particular acquisition seems to make a lot of sense on paper.

Get the top digital health stories right in your inbox

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Digital Health Wire team

You're all set!